Oktay OLMUŞÇELİK, Ömür Gökmen SEVİNDİK, Ali MERT, Hülya BİLGEN, Cem ERDOĞAN, Rümeysa DİNLEYİCİ, Aliihsan GEMİCİ, Hüseyin Saffet BEKÖZ, Abdullah KANSU

A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma

Background/aim: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there lacks either a specific treatment or a vaccine to treat COVID-19. Convalescent plasma (CP) was previously used successfully to treat SARS-CoV-1 and MERS infections. Health authority in Turkey has published a guideline to integrate this promising option in the treatment process of patients who are prone to high risk of developing severe COVID 19. Materials and Methods: Forty consecutive patients who had received CP at our center were included in the study. Demographics, COVID-19 specific parameters, biomarkers to detect the severity of COVID-19 infection and outcome variables were collected retrospectively. The correlation between outcome variables and the independent predictors of the outcome were reported. Results: Median age of the patients was 57.5 and 72.5% were male. At least one COVID-19 PCR test was confirmed to be positive in 75% of patients. Remaining 25% had a Chest-CT which was reported to be compatible with an ongoing COVID-19. All patients (100%) were classified as having severe COVID-19 infection. Over a half of the patients harbored an oxygen saturation of less than 90 despite of a continuous 5 L/min support of O2 . 82.5% of the patients had a need for mechanical ventilation and 45.5% had a need for invasive mechanical ventilation. Nine out of 10 patients who have received CP outside ICU have totally recovered from COVID-19 at a median of 9 days, and a half of the patients who needed invasive mechanical ventilation were successfully free of mechanical ventilation support and managed to recover from COVID-19. Conclusion: According to the results of this study, CP is an efficient conjunct to conventional therapy against COVID-19 with a favorable safety profile.

PDF

___

1. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. The Journal of Clinical Investigation 2020; 130 (4): 1545-1548. doi: 10.1172/JCI138003
2. Xie M, Chen Q. Insight into 2019 novel coronavirus - an updated interim review and lessons from SARS-CoV and MERS-CoV. International Journal of Infectious Diseases 2020; 94: 119-124. doi: 10.1016/j.ijid.2020.03.071
3. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infectious Diseases 2020; 20 (4): 398-400. doi: 10.1016/S1473-3099(20)30141-9
4. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation 2020; 130 (6): 2757-2765. doi: 10.1172/JCI138745
5. Al-Riyami AZ, Schäfer R, Berg K, Bloch EM, Escourt L et al. Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities. Vox Sanguinis 2020. doi: 10.1111/vox.12973
6. Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat critically ill patients. British Medical Journal 2020; 368. doi: 10.1136/bmj.m1256
7. Shen C, Wang Z, Zhao F, Yang Y, Li J et al.Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. The Journal of the American Medical Association 2020; 323 (16): 1582-1589. doi: 10.1001/jama.2020.4783
8. Duan K, Liuc B, Lid C, Zhange H, Yuf T et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America 2020;117 (17): 9490-9496. doi: 10.1073/ pnas.2004168117
9. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. Journal of Clinical Investigation 2020; 130 (9): 4791-4797. doi: 10.1172/JCI140200
10. Ye M, Fu D, Ren Y, Wang F, Wang D et al.Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. Journal of Medical Virology 2020; 1-12. doi: 10.1002/ jmv.25882
11. Altuntas F, Ata N, Yigenoglu TN, Bascı S, Dal MS et al.Convalescent plasma therapy in patients with COVID-19. Transfusionand Apheresis Science 2020. doi: 10.1016/j. transci.2020.102955